Celldex Therapeutics (CLDX) Stock Price, News & Analysis

Company Overview

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Key Stats

• Today's Range: $20.64 to $21.23
• 50-Day Range: $15.13 to $21.36
• 52-Week Range: $14.40 to $47.00
• Volume: 598,699 shs
• Average Volume: 883,869 shs
• Market Capitalization: $1.37 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $55.30
• Consensus Rating: Moderate Buy

Celldex Therapeutics Stock Analysis - MarketRank™

Celldex Therapeutics scored higher than 40% of companies evaluated by MarketBeat, and ranked 539th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Celldex Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Celldex Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Celldex Therapeutics are expected to decrease in the coming year, from ($2.48) to ($3.34) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Celldex Therapeutics is -8.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Celldex Therapeutics is -8.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Celldex Therapeutics has a P/B Ratio of 2.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.76% of the float of Celldex Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Celldex Therapeutics has a short interest ratio ("days to cover") of 11, which indicates bearish sentiment.

Change versus previous month

Short interest in Celldex Therapeutics has recently increased by 5.78%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Celldex Therapeutics does not currently pay a dividend.

Dividend Growth

Celldex Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

13.76% of the float of Celldex Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Celldex Therapeutics has a short interest ratio ("days to cover") of 11, which indicates bearish sentiment.

Change versus previous month

Short interest in Celldex Therapeutics has recently increased by 5.78%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 1.26

News Sentiment

Celldex Therapeutics has a news sentiment score of 1.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 16 news articles for Celldex Therapeutics this week, compared to 4 articles on an average week.

MarketBeat Follows

1 people have added Celldex Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Celldex Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.80% of the stock of Celldex Therapeutics is held by insiders.

CLDX Stock Analysis - Frequently Asked Questions

How have CLDX shares performed this year?

Celldex Therapeutics' stock was trading at $25.27 at the beginning of the year. Since then, CLDX stock has decreased by 18.2% and is now trading at $20.66.
View the best growth stocks for 2025 here.

How were Celldex Therapeutics' earnings last quarter?

Celldex Therapeutics, Inc. (NASDAQ:CLDX) posted its earnings results on Thursday, February, 27th. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping analysts' consensus estimates of ($0.73) by $0.02. The biopharmaceutical company earned $1.18 million during the quarter, compared to the consensus estimate of $1.25 million. Celldex Therapeutics had a negative trailing twelve-month return on equity of 19.75% and a negative net margin of 1,544.32%.

When did Celldex Therapeutics' stock split?

Celldex Therapeutics shares reverse split on Monday, February 11th 2019. The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 8th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Who are Celldex Therapeutics' major shareholders?

Celldex Therapeutics' top institutional shareholders include Bank of New York Mellon Corp (0.26%), Mirador Capital Partners LP (0.19%), Rhumbline Advisers (0.15%) and Alps Advisors Inc. (0.08%). Insiders that own company stock include Anthony S Marucci, Samuel Bates Martin, Richard M Wright, Elizabeth Crowley, Margo Heath-Chiozzi, Diane C Young and Sarah Cavanaugh.
View institutional ownership trends.

How do I buy shares of Celldex Therapeutics?

Shares of CLDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Celldex Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Celldex Therapeutics investors own include Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA), Tesla (TSLA), Netflix (NFLX), Alphabet (GOOG) and Visa (V).

Company Calendar

• Last Earnings: 2/27/2025
• Today: 5/02/2025
• Next Earnings (Estimated): 5/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Diagnostic substances
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CLDX
• CIK: 744218
• Web: www.celldex.com
• Phone: (908) 454-7120
• Fax: 908-454-1911
• Employees: 150
• Year Founded: 1983

Price Target and Rating

• Average Stock Price Target: $55.30
• High Stock Price Target: $80.00
• Low Stock Price Target: $36.00
• Potential Upside/Downside: +167.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.90
• Research Coverage: 10 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.45)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-141,430,000.00
• Net Margins: -1,544.32%
• Pretax Margin: -1,544.32%
• Return on Equity: -19.75%
• Return on Assets: -18.86%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 24.27
• Quick Ratio: 24.27

Sales & Book Value

• Annual Sales: $7.02 million
• Price / Sales: 195.82
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.08 per share
• Price / Book: 2.28

Miscellaneous

• Outstanding Shares: 66,384,000
• Free Float: 63,823,000
• Market Cap: $1.37 billion
• Optionable: Optionable
• Beta: 1.59